Jazz Pharmaceuticals, Inc. Second Quarter Earnings Sneak Peek

Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) will unveil its latest earnings on Thursday, July 28, 2011. A specialty pharmaceutical company, which is focused on developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.

Jazz Pharmaceuticals, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for profit of 69 cents per share, a rise of more than fourfold from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 61 cents. For the year, analysts are projecting net income of $2.78 per share, a rise of more than twofold from last year.

Past Earnings Performance: The company has beaten estimates the last four quarters and is coming off a quarter where it topped forecasts by 3 cents, reporting profit of 52 cents per share against a mean estimate of net income of 49 cents per share.

Get more Earnings Cheat Sheets with our in depth coverage of earnings season >>

Wall St. Revenue Expectations: On average, analysts predict $61.9 million in revenue this quarter, a rise of 52.8% from the year ago quarter. Analysts are forecasting total revenue of $252.5 million for the year, a rise of 45.3% from last year’s revenue of $173.8 million.

Analyst Ratings: Analysts are bullish on this stock with four analysts rating it as a buy, none rating it as a sell and two rating it as a hold.

Key Stats:

Revenue has risen the past four quarters. Revenue increased 44.7% to $50.9 million in first quarter. The figure rose 39.4% in the fourth quarter of the last fiscal year from the year earlier, climbed 45.3% in the third quarter of the last fiscal year from the year-ago quarter and 8.6% in the second quarter of the last fiscal year.

Competitors to Watch: Cephalon, Inc. (NASDAQ:CEPH), Forest Laboratories, Inc. (NYSE:FRX), Transcept Pharmaceuticals, Inc. (NASDAQ:TSPT), Pfizer Inc. (NYSE:PFE), GlaxoSmithKline plc (NYSE:GSK), Eli Lilly & Co. (NYSE:LLY), Abbott Laboratories (NYSE:ABT), Caraco Pharmaceutical Laboratories Ltd. (AMEX:CPD), Watson Pharmaceuticals, Inc. (NYSE:WPI), and McKesson Corporation (NYSE:MCK).

Stock Price Performance: During May 25, 2011 to July 22, 2011, the stock price had risen $11.47 (42.3%) from $27.11 to $38.58. The stock price saw one of its best stretches over the last year between June 13, 2011 and June 23, 2011 when shares rose for nine-straight days, rising 19% (+$5.10) over that span. It saw one of its worst periods between May 9, 2011 and May 17, 2011 when shares fell for seven-straight days, falling 11.1% (-$3.39) over that span. Shares are up $18.90 (+96%) year to date.

(Source: Xignite Financials)

Get more Earnings Cheat Sheets with our in depth coverage of earnings season >>